It’s an exciting month for EpiAxis Therapeutics as we return to face-to-face biotech conferences after more than two years of virtual attendance.

Chairman Dr David Fuller is currently representing EpiAxis at the ASCO 2022 Annual Meeting in Chicago; while CEO Dr Jeremy Chrisp will attend the BIO International Convention from June 13-16, 2022 at San Diego Convention Center.

The American Society of Clinical Oncology (ASCO), the world’s premier oncology gathering, opened in Chicago on June 3 for the first time since 2019, bringing the largest crowd of cancer care leaders together since the start of the pandemic. The 2022 ASCO Annual Meeting Program is offering presentations on the latest research in cancer care and extensive networking opportunities. This year’s program will feature over 200 sessions complementing the meeting’s theme: Advancing Equitable Cancer Care Through Innovation.

ASCO organisers said last week more than 36,000 people had registered for the conference and 80% were planning to attend the meeting in person.

“It is great to see ASCO return to Chicago and have the opportunity to interact with with industry colleagues again after the COVID-19 pandemic,” Dr Fuller said. “Each year, the ASCO conference brings together oncologists from all around the globe and is attended by medical, educational and industrial stakeholders involved in the field of oncology worldwide. It’s an invaluable opportunity to share EpiAxis’ epigenetic advances with a highly engaged audience.”

Dr Jeremy Chrisp is looking forward to attending the 2022 BIO International Convention later this month. The convention will feature more than 100 interactive sessions across four days, covering a variety of therapeutic areas, business development, digital health, patient advocacy and next generation biotherapeutics.

“We are seeking new investors to advance our pioneering epigenetic program into the clinic and the Bio International Convention will be an excellent opportunity to update the industry on our progress in the epigenetic space,” Dr Chrisp said.

“We are looking to continue our discussions with potential pharma partners who are receptive to our novel first-in-class oncology therapeutics. Epigenetics is an emerging and active therapeutic area and offers the prospect of a less toxic cancer treatment by re-programming both cancer and immune cells for superior outcomes.

“Importantly, we believe through face-to-face discussion, the underlying value in our programs can best be communicated. EpiAxis is now moving into the next phase of development and is seeking to raise US $12million (tranched) to take us from lead candidate selection through IND filing and an initial Phase 1/2 dose escalation expansion study.”

For more information about EpiAxis Therapeutics and partnering opportunities for its pipeline drug candidates, please contact:

Dr Jeremy Chrisp
Phone: +61 421 012 268
j.chrisp@epiaxistherapeutics.com